Price
1,303.5
-1.18%52W Range
Market Cap
₹1,08,795.72 Cr
Traded: ₹707.94 Cr (0.65%) 0.0x
Free Float: ₹10,150.64 Cr (6.97% of FF traded)
Volume · 60D trend
54.24 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Held by ETFs
68 ETFs hold drreddy · sorted by weight
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +8.0% | +12.0% | +11.0% | -- | +3.0% | Decelerating |
| Profit | +7.0% | +17.0% | -3.0% | -- | -24.0% | Decelerating |
| Return | +8.0% | +4.0% | +12.0% | +6.0% | -- | Stable |
| ROE | +15.0% | +17.0% | +17.0% | -- | -- | Stable |
Quarterly Results
Mar 2026
12 MayDec 2025
21 JanSep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Shareholding Pattern
LAX.SH
Exchange Filings
50Dr. Reddy''s Laboratories Limited has informed the Exchange that the Annual Report in Form 20F for the fiscal year ended March 31, 2026 has been filed with United States Securities and ....
Annual Secretarial Compliance certificate for the year ended March 31, 2026
Disclosure under Regulation 30 of SEBI (LODR) 2015, regarding Press release viz. "Dr. Reddy''s Laboratories to Ring the Closing Bell at New York Stock Exchange."
Copies of newspaper publication
Transcript of Earnings call recordings held on May 12, 2026
Intimation of Analyst/Investor meet
Announcement under Regulation 30 (LODR) Regulations, 2015 regarding issuance of Press Release viz. "Dr. Reddy''s Laboratories Launches its Generic Semaglutide Injection in Canada".
Copies of newspaper publication
Recording of Earnings call
Investor presentation for Q4 and FY 2026 Audited Financial Results
Investor presentation for Q4 and FY 2026 Audited Financial Results
Appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors
Recommendation of final dividend of INR Rs. 8/- per equity share for FY 2025-26
Announcement under Regulation 30 (LODR) - Change in Management
Fixing of record date as July 10, 2026 for the purpose of payment of final dividend for FY 2025-26
Audited Financial Results for the year ended March 31, 2026
Outcome of Board Meeting held on May 12, 2026
Intimation of Analyst/Investor meet
Grant of Employee Stock Options
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Intimation of Earnings call
Copies of newspaper publication
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on April 24, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on April 23, 2026, with reference to news appeared in https://www.cnbctv18.com/ dated April 23, 2026 quoting "Dr. Reddy''s ....
Board meeting intimation for recommending Final Dividend, if any, for the Financial Year 2025-26
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended March 31, 2026
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Allotment of Employee Stock Options
Revised Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve To consider the Audited ....
Intimation of Board meeting date and Trading Window closure
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Allotment of Employee Stock Options
Copies of newspaper publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Intimation of Analyst meet
Disclosure under Regulation 30 of the SEBI Listing Regulations
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Allotment of Employee Stock Options
Schedule of Analyst meet
Copies of newspaper publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Schedule of Analyst meet
Annual Reports
14Credit Ratings
6Concalls
30Jan 2026
31 Jan 2026Jan 2026
31 Jan 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021May 2020
31 May 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019Apr 2017
30 Apr 2017Oct 2016
31 Oct 2016Jul 2016
31 Jul 2016Apr 2016
30 Apr 2016Nov 2015
30 Nov 2015Detailed Financials
Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,546 | 8,753 | 8,828 | 8,572 | 8,528 | 8,381 | 8,038 | 7,696 | 7,114 | 7,237 | 6,903 | 6,758 | 6,315 | 6,790 |
| Expenses | 7,164 | 6,866 | 6,818 | 6,398 | 6,530 | 6,108 | 5,962 | 5,566 | 5,283 | 5,214 | 4,894 | 4,696 | 4,781 | 4,851 |
| Operating Profit | 382 | 1,888 | 2,010 | 2,174 | 1,998 | 2,273 | 2,076 | 2,130 | 1,831 | 2,023 | 2,008 | 2,062 | 1,534 | 1,939 |
| OPM % | 5.0% | 22.0% | 23.0% | 25.0% | 23.0% | 27.0% | 26.0% | 28.0% | 26.0% | 28.0% | 29.0% | 31.0% | 24.0% | 29.0% |
| Other Income | 480 | 271 | 330 | 290 | 528 | 154 | 314 | 193 | 201 | 219 | 319 | 178 | 146 | 65 |
| Interest | 106 | 94 | 91 | 83 | 66 | 82 | 76 | 60 | 59 | 39 | 35 | 37 | 35 | 42 |
| Depreciation | 557 | 521 | 505 | 476 | 455 | 471 | 397 | 381 | 368 | 374 | 376 | 353 | 316 | 324 |
| Profit Before Tax | 200 | 1,543 | 1,745 | 1,905 | 2,005 | 1,874 | 1,917 | 1,883 | 1,605 | 1,829 | 1,917 | 1,850 | 1,329 | 1,638 |
| Tax % | -11.0% | 23.0% | 23.0% | 26.0% | 21.0% | 25.0% | 30.0% | 26.0% | 18.0% | 24.0% | 23.0% | 24.0% | 28.0% | 24.0% |
| Net Profit | 221 | 1,190 | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 | 1,392 | 1,310 | 1,381 | 1,482 | 1,405 | 960 | 1,244 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 2.6 | 14.5 | 16.1 | 17.0 | 19.1 | 16.9 | 15.1 | 16.7 | 15.7 | 16.6 | 17.8 | 16.9 | 11.5 | 14.9 |
| Sales Growth (YoY) | -11.5% | 4.4% | 9.8% | 11.4% | 19.9% | 15.8% | 16.4% | 13.9% | 12.7% | 6.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -13.8% | -0.8% | 3.0% | 0.5% | 1.8% | 4.3% | 4.4% | 8.2% | -1.7% | 4.8% | 2.1% | 7.0% | -7.0% | -- |
| OP Growth (YoY) | -80.9% | -16.9% | -3.2% | 2.1% | 9.1% | 12.4% | 3.4% | 3.3% | 19.4% | 4.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | -79.8% | -6.1% | -7.5% | 8.8% | -12.1% | 9.5% | -2.5% | 16.3% | -9.5% | 0.7% | -2.6% | 34.4% | -20.9% | -- |
| Profit Growth (YoY) | -- | -14.0% | 7.0% | 2.0% | 22.0% | 2.0% | -15.0% | -1.0% | 36.0% | 11.0% | 33.0% | 18.0% | 890.0% | 75.0% |
| EPS Growth (YoY) | -86.1% | -14.4% | 7.2% | 1.8% | 21.6% | 2.3% | -15.3% | -1.1% | 36.2% | 10.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -81.7% | -10.2% | -5.0% | -11.0% | 12.7% | 12.6% | -9.8% | 6.3% | -5.2% | -6.8% | 5.3% | 46.3% | -22.8% | -- |
| OP Margin | 5.1% | 21.6% | 22.8% | 25.4% | 23.4% | 27.1% | 25.8% | 27.7% | 25.7% | 27.9% | 29.1% | 30.5% | 24.3% | 28.6% |
| Net Margin | 2.9% | 13.6% | 15.1% | 16.4% | 18.6% | 16.8% | 16.7% | 18.1% | 18.4% | 19.1% | 21.5% | 20.8% | 15.2% | 18.3% |
| Material Cost % | -- | 35.4% | 35.4% | 32.8% | 33.4% | 30.8% | 29.4% | 28.4% | 29.4% | 30.1% | 29.0% | 28.7% | 30.1% | 29.5% |
| Employee Cost % | -- | 18.1% | 16.4% | 17.5% | 16.4% | 16.3% | 17.4% | 18.4% | 18.0% | 17.6% | 18.6% | 17.6% | 20.2% | 17.3% |
| P/S | 3.23 | 3.08 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 25.92 | 19.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.87 | 2.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |